Statement of Changes in Beneficial Ownership (4)
March 16 2017 - 4:37PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
McGuire Jonathan Will
|
2. Issuer Name
and
Ticker or Trading Symbol
SECOND SIGHT MEDICAL PRODUCTS INC
[
EYES
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
Chief Executive Officer
|
(Last)
(First)
(Middle)
12744 SAN FERNANDO ROAD, SUITE 400
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/14/2017
|
(Street)
SYLMAR, CA 91342
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
3/14/2017
|
3/14/2017
|
A
|
|
6794
|
A
|
$1.47
|
59798
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Warrant to Purchase Common Stock
|
$1.47
|
3/14/2017
|
|
A
|
|
6794
(1)
|
|
3/14/2017
|
3/14/2022
|
Common Stock
|
6794
|
(1)
|
6794
|
D
|
|
Non-Qualified Stock Option (right to buy)
|
$1.97
|
|
|
|
|
|
|
1/3/2018
(2)
|
1/3/2027
|
Common Stock
|
571330
|
|
571330
|
D
|
|
Non-Qualified Stock Option (right to buy)
|
$4.1
|
|
|
|
|
|
|
1/21/2017
(2)
|
1/21/2026
|
Common Stock
|
21290
|
|
21290
|
D
|
|
Non-Qualified Stock Option (right to buy)
|
$12.43
|
|
|
|
|
|
|
8/17/2016
(2)
|
8/17/2025
|
Common Stock
|
420000
|
|
420000
|
D
|
|
Restricted Stock Unit (RSU)
|
(3)
|
|
|
|
|
|
|
8/17/2016
(2)
|
8/17/2019
|
Common Stock
|
190000
|
|
118750
|
D
|
|
Explanation of Responses:
|
(
1)
|
Common stock and warrants reported on this Form 4 pursuant to an exercise of subscription rights previously distributed by the Company to all holders of the Company's common stock. Each stockholder received a right to invest $0.47 for every share held of record on February 10, 2017, the record date, to purchase units consisting of one share of common stock and one warrant to purchase one share of common stock. The final allocation numbers of units were distributed on March 14, 2017.
|
(
2)
|
Options and RSUs vest over a 4 year term, with 25% vesting on the date exercisable as set forth in this Form 4 and thereafter vesting in 12 equal quarterly installments of 6.25%.
|
(
3)
|
Each restricted stock unit represents a contingent right to receive one share of common stock of the Company.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
McGuire Jonathan Will
12744 SAN FERNANDO ROAD
SUITE 400
SYLMAR, CA 91342
|
|
|
Chief Executive Officer
|
|
Signatures
|
/s/ Jonathan Will McGuire
|
|
3/16/2017
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Apr 2024 to May 2024
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Second Sight Medical Products Inc (NASDAQ): 0 recent articles
More Second Sight Medical Products Inc News Articles